In 2000, Yemen joined the WHO global efforts to eliminate lymphatic filariasis (LF) as a public health problem by initiating a National LF Elimination Programme (NLFEP), that was fully integrated with the National Leprosy Elimination Programme (NLEP), the Ministry of Public Health and Population. This article reviews the NLFEP extensive efforts and interventions to eliminate LF in Yemen. LF mapping was started in 2000, followed by five annual rounds of mass drug administration (MDA) with ivermectin and albendazole in 8 implementation units (IUs) during 2002-2006. The epidemiological coverage for all MDA rounds was ≥80%. Based on WHO guidelines of 2005, MDA was stopped in 7 IUs, additional MDA rounds were continued in one IU until 2011. Microfilaremia monitoring and evaluation, and MDA stopping surveys were conducted based on WHO guidelines of 2005 and 2011. Information about the presence of patients suffering from lymphoedema/elephantiasis and hydrocele was collected, and basic care provided to all chronic cases by NLEP coordinators, trained on LF morbidity management and disability prevention (MMDP). As of 2017, a total of 610 lymphoedema patients were trained on self-management, and 31 hydrocele patients were referred to local General Hospitals for surgery. The NLFEP made excellent progress due to integration with NLEP, strong collaboration with national and international bodies, intensive training and supervision, and the use of robust advocacy for mobilization of endemic communities. Transmission assessment surveys (TAS), conducted in 2013 and 2016, indicated 0% antigenemia levels in schoolchildren in the 8 IUs. Thus, after almost two decades of sustained effort, Yemen met the WHO criteria for successful elimination of LF as a public health problem. In 2019, WHO validated Yemen as the second country in the WHO’ Eastern Mediterranean Region to successfully eliminate LF as a public health problem.

2000年，也门加入了世界卫生组织在全球范围内消除淋巴丝虫病（LF）的公共卫生问题，发起了一项国家LF消除计划（NLFEP），该计划已与国家麻风病消除计划（NLEP）完全整合卫生与人口。本文回顾了NLFEP在也门消除LF的广泛努力和干预措施。LF绘制始于2000年，随后在2002-2006年期间，在8个实施单位（IUs）中进行了伊维菌素和阿苯达唑的5年一轮的大规模药物管理（MDA）。所有MDA轮次的流行病学覆盖率均≥80％。根据世界卫生组织2005年的指南，MDA在7个IU中停止，另外一轮IU中继续进行MDA直到2011年。根据世界卫生组织2005年和2011年的指南进行了MDA和MDA停药调查。收集了有关淋巴水肿/大象病和鞘膜积液患者的信息，并且由NLEP协调员为所有慢性病例提供了关于LF发病率管理和残疾培训的基本护理预防（MMDP）。截至2017年，共有610名淋巴水肿患者接受了自我管理培训，有31名鞘膜积液患者被转诊至当地综合医院进行手术。NLFEP由于与NLEP的整合，与国家和国际机构的紧密合作，强化培训和监督以及动员了当地社区的积极倡导而取得了卓越的进展。在2013年和2016年进行的传播评估调查（TAS）表明，在8个IU中，学童的抗原血症水平为0％。因此，经过将近二十年的不懈努力，也门达到了世界卫生组织的标准，成功消除了作为公共卫生问题的LF。2019年，世卫组织确认也门是世卫组织东地中海区域第二个成功消除LF作为公共卫生问题的国家。